You are here

  • Home
  • Archive
  • Volume 12, Issue 7
  • FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription

Authors

  • Xuemei Li The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, ChinaGansu Provincial Key Laboratory of Environmental Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China PubMed articlesGoogle scholar articles
  • Lei Gao The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, ChinaGansu Provincial Key Laboratory of Environmental Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China PubMed articlesGoogle scholar articles
  • Bofang Wang The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, ChinaGansu Provincial Key Laboratory of Environmental Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China PubMed articlesGoogle scholar articles
  • Jike Hu The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, ChinaGansu Provincial Key Laboratory of Environmental Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China PubMed articlesGoogle scholar articles
  • Yang Yu The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, ChinaGansu Provincial Key Laboratory of Environmental Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China PubMed articlesGoogle scholar articles
  • Baohong Gu Department of Surgical Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China PubMed articlesGoogle scholar articles
  • Lin Xiang Department of Pathology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China PubMed articlesGoogle scholar articles
  • Xiaomei Li The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, ChinaGansu Provincial Key Laboratory of Environmental Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China PubMed articlesGoogle scholar articles
  • Haiyuan Li Department of Surgical Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China PubMed articlesGoogle scholar articles
  • Tao Zhang Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, China PubMed articlesGoogle scholar articles
  • Yunpeng Wang The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, ChinaGansu Provincial Key Laboratory of Environmental Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China PubMed articlesGoogle scholar articles
  • Chenhui Ma The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, ChinaGansu Provincial Key Laboratory of Environmental Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China PubMed articlesGoogle scholar articles
  • Jiahong Dong Department of Hepatobiliary and Pancreas Surgery, Tsinghua University, Beijing, China PubMed articlesGoogle scholar articles
  • Jianrong Lu Departments of Biochemistry and Molecular Biology, Florida College of Medicine, Gainesville, Florida, USA PubMed articlesGoogle scholar articles
  • Alexandra Lucas Arizona State University, Tempe, Arizona, USA PubMed articlesGoogle scholar articles
  • Hao Chen Department of Surgical Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, ChinaThe Key Laboratory of Humanized Animal Models, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China PubMed articlesGoogle scholar articles

Citation

Li X, Gao L, Wang B, et al
FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription
Journal for ImmunoTherapy of Cancer 2024;12:e009565. doi: 10.1136/jitc-2024-009565
Online issue publication 
July 25, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.